Literature DB >> 23231684

Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2.

So Young Kim1, Jung Eun Koo, Yun Jee Seo, Nisha Tyagi, Eunshil Jeong, Jaeyoung Choi, Kyung-Min Lim, Zee-Yong Park, Joo Young Lee.   

Abstract

BACKGROUND AND
PURPOSE: Toll-like receptors (TLRs) play a crucial role in recognizing invading pathogens and endogenous danger signal to induce immune and inflammatory responses. Since dysregulation of TLRs enhances the risk of immune disorders and chronic inflammatory diseases, modulation of TLR activity by phytochemicals could be useful therapeutically. We investigated the effect of caffeic acid phenethyl ester (CAPE) on TLR-mediated inflammation and the underlying regulatory mechanism. EXPERIMENTAL APPROACH: Inhibitory effects of CAPE on TLR4 activation were assessed with in vivo murine skin inflammation model and in vitro production of inflammatory mediators in macrophages. In vitro binding assay, cell-based immunoprecipitation study and liquid chromatography-tandem mass spectrometry analysis were performed to determine lipopolysaccharide (LPS) binding to MD2 and to identify the direct binding site of CAPE in MD2. KEY
RESULTS: Topical application of CAPE attenuated dermal inflammation and oedema induced by intradermal injection of LPS (a TLR4 agonist). CAPE suppressed production of inflammatory mediators and activation of NFκB and interferon-regulatory factor 3 (IRF3) in macrophages stimulated with LPS. CAPE interrupted LPS binding to MD2 through formation of adduct specifically with Cys133 located in hydrophobic pocket of MD2. The inhibitory effect on LPS-induced IRF3 activation by CAPE was not observed when 293T cells were reconstituted with MD2 (C133S) mutant. CONCLUSIONS AND IMPLICATIONS: Our results show a novel mechanism for anti-inflammatory activity of CAPE to prevent TLR4 activation by interfering with interaction between ligand (LPS) and receptor complex (TLR4/MD2). These further provide beneficial information for the development of therapeutic strategies to prevent chronic inflammatory diseases.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23231684      PMCID: PMC3623063          DOI: 10.1111/bph.12091

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Toll-like receptors as targets for immune disorders.

Authors:  Brian Keogh; Andrew E Parker
Journal:  Trends Pharmacol Sci       Date:  2011-04-27       Impact factor: 14.819

2.  The role of disulfide bonds in the assembly and function of MD-2.

Authors:  Gregory E D Mullen; Margaret N Kennedy; Alberto Visintin; Alessandra Mazzoni; Cynthia A Leifer; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

3.  Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester.

Authors:  K Frenkel; H Wei; R Bhimani; J Ye; J A Zadunaisky; M T Huang; T Ferraro; A H Conney; D Grunberger
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

4.  Essential role of MD-2 in TLR4-dependent signaling during Helicobacter pylori-associated gastritis.

Authors:  Shunji Ishihara; Mohammad Azharul Karim Rumi; Yasunori Kadowaki; Cesar Francisco Ortega-Cava; Takafumi Yuki; Nagisa Yoshino; Youichi Miyaoka; Hideaki Kazumori; Norihisa Ishimura; Yuji Amano; Yoshikazu Kinoshita
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

5.  Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism.

Authors:  Alain P Gobert; Jean-Christophe Bambou; Catherine Werts; Viviane Balloy; Michel Chignard; Anthony P Moran; Richard L Ferrero
Journal:  J Biol Chem       Date:  2003-10-22       Impact factor: 5.157

6.  IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

Authors:  Katherine A Fitzgerald; Sarah M McWhirter; Kerrie L Faia; Daniel C Rowe; Eicke Latz; Douglas T Golenbock; Anthony J Coyle; Sha-Mei Liao; Tom Maniatis
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

7.  Separate functional domains of human MD-2 mediate Toll-like receptor 4-binding and lipopolysaccharide responsiveness.

Authors:  Fabio Re; Jack L Strominger
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

8.  Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization.

Authors:  Shin-ichiroh Saitoh; Sachiko Akashi; Takenao Yamada; Natsuko Tanimura; Makiko Kobayashi; Kazunori Konno; Fumi Matsumoto; Koichi Fukase; Shoichi Kusumoto; Yoshinori Nagai; Yutaka Kusumoto; Atsushi Kosugi; Kensuke Miyake
Journal:  Int Immunol       Date:  2004-06-07       Impact factor: 4.823

9.  RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.

Authors:  Etienne Meylan; Kim Burns; Kay Hofmann; Vincent Blancheteau; Fabio Martinon; Michelle Kelliher; Jürg Tschopp
Journal:  Nat Immunol       Date:  2004-04-04       Impact factor: 25.606

10.  Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling.

Authors:  A B Schromm; E Lien; P Henneke; J C Chow; A Yoshimura; H Heine; E Latz; B G Monks; D A Schwartz; K Miyake; D T Golenbock
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

View more
  16 in total

1.  Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1.

Authors:  Sang Hyeon Yeon; Moon Jung Song; Hye-Ri Kang; Joo Young Lee
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis.

Authors:  Yi Wang; Xiaoou Shan; Gaozhi Chen; Lili Jiang; Zhe Wang; Qilu Fang; Xing Liu; Jingying Wang; Yali Zhang; Wencan Wu; Guang Liang
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

3.  Tannic acid prevents macrophage-induced pro-fibrotic response in lung epithelial cells via suppressing TLR4-mediated macrophage polarization.

Authors:  Ayyanar Sivanantham; Dhamotharan Pattarayan; Nandhine Rajasekar; Adithi Kannan; Lakshmanan Loganathan; Ramalingam Bethunaickan; Santanu Kar Mahapatra; Rajaguru Palanichamy; Karthikeyan Muthusamy; Subbiah Rajasekaran
Journal:  Inflamm Res       Date:  2019-09-05       Impact factor: 4.575

Review 4.  Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.

Authors:  Swati Bhattacharyya; Kim S Midwood; Hang Yin; John Varga
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-10-01       Impact factor: 4.730

Review 5.  Allergic Inflammation: Effect of Propolis and Its Flavonoids.

Authors:  Nada Oršolić
Journal:  Molecules       Date:  2022-10-08       Impact factor: 4.927

6.  Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.

Authors:  Francesco Peri; Valentina Calabrese
Journal:  J Med Chem       Date:  2013-11-20       Impact factor: 7.446

7.  X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes.

Authors:  Jung Eun Koo; Seung Won Shin; Soong Ho Um; Joo Young Lee
Journal:  Mol Cancer       Date:  2015-05-15       Impact factor: 27.401

8.  Association of neonatal necrotizing enterocolitis with myeloid differentiation-2 and GM2 activator protein genetic polymorphisms.

Authors:  Wei Zhou; Weiming Yuan; Longguang Huang; Ping Wang; Xiao Rong; Juan Tang
Journal:  Mol Med Rep       Date:  2015-03-17       Impact factor: 2.952

9.  Gambogic Acid Disrupts Toll-like Receptor4 Activation by Blocking Lipopolysaccharides Binding to Myeloid Differentiation Factor 2.

Authors:  Jin Young Lee; Byung Ho Lee; Joo Young Lee
Journal:  Toxicol Res       Date:  2015-03

Review 10.  Kdo2 -lipid A: structural diversity and impact on immunopharmacology.

Authors:  Xiaoyuan Wang; Peter J Quinn; Aixin Yan
Journal:  Biol Rev Camb Philos Soc       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.